Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Sellas Life Sciences Group Inc

Healthcare US SLS

8.7741USD
0.72(8.99%)

Last update at 2026-06-22T15:05:00Z

Day Range

8.348.82
LowHigh

52 Week Range

0.501.91
LowHigh

Fundamentals

  • Previous Close 8.05
  • Market Cap79.70M
  • Volume3204019
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.90M
  • Diluted EPS TTM-1.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -41.30100M -20.93600M -16.77400M -19.37300M -29.04800M
Minority interest - - - - -
Net income -40.65200M -20.69900M -16.75700M -19.29200M -27.67000M
Selling general administrative 12.58M 11.32M 9.60M 9.92M 12.77M
Selling and marketing expenses - - - - -
Gross profit 0.90M 7.40M 0.00190M - 0.00000M
Reconciled depreciation - - 0.28M - 0.00000M
Ebit -41.95000M -25.29400M -16.75700M -20.04100M -35.70300M
Ebitda -42.28200M -29.64600M 26.52M -14.92500M -33.39600M
Depreciation and amortization -0.33200M -4.35200M 0.28M 5.12M 2.31M
Non operating income net other - - 0.21M - -
Operating income -41.95000M -25.29400M -16.98200M -20.04100M -31.08900M
Other operating expenses 42.95M 32.89M 18.88M 17.21M 31.09M
Interest expense -0.64900M 4.36M 0.39M 0.12M 0.27M
Tax provision 0.00000M -0.23700M -0.01700M -0.08100M -1.37800M
Interest income 0.32M 0.00600M 0.03M 0.12M 0.27M
Net interest income 0.32M 0.00600M 0.03M 0.12M -0.26600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.64900M -0.23700M -0.01700M -0.08100M -1.37800M
Total revenue 1.00M 7.60M 0.00190M 0.00000M 0.00000M
Total operating expenses 42.85M 32.69M -18.88200M 17.21M 31.09M
Cost of revenue 0.10M 0.20M - - 0.00000M
Total other income expense net 0.65M 4.36M 16.97M 0.67M 2.31M
Discontinued operations - - - - -
Net income from continuing ops -41.30100M -20.69900M -16.75700M -19.29200M -27.64800M
Net income applicable to common shares -41.30100M -20.69900M -16.83500M -27.95100M -41.25100M
Preferred stock and other adjustments - - - - 4.44M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.40M 20.94M 26.27M 46.05M 16.61M
Intangible assets - - - 5.70M 5.70M
Earning assets - - - - -
Other current assets 0.54M 0.05M 0.03M 0.03M 0.08M
Total liab 14.38M 16.09M 5.93M 18.09M 10.52M
Total stockholder equity -7.97600M 4.85M 20.35M 27.96M 6.09M
Deferred long term liab - - - 0.24M 0.26M
Other current liab 7.65M 11.79M 0.16M 1.91M 1.17M
Common stock 0.00300M 0.00200M 0.00200M 0.00100M 0.00500M
Capital stock 0.00300M 0.00200M 0.00200M 0.00100M 0.00500M
Retained earnings -217.24400M -179.90400M -138.60300M -117.90400M -101.14700M
Other liab - 0.00400M 0.34M 4.93M 5.23M
Good will 1.91M 1.91M 1.91M 1.91M 1.91M
Other assets 0.00000M 0.40M 0.59M 7.21M 0.54M
Cash 2.63M 17.12M 21.36M 35.30M 7.28M
Cash and equivalents - - - - -
Total current liabilities 13.73M 15.52M 4.98M 12.34M 5.29M
Current deferred revenue - - 2.48M 5.60M -
Net debt -1.72400M -16.18000M -20.54700M -34.31100M -7.06000M
Short term debt 0.45M 0.37M 0.20M 0.17M 0.22M
Short long term debt - - - - -
Short long term debt total 0.91M 0.94M 0.81M 0.99M 0.22M
Other stockholder equity 209.26M 184.75M 158.95M 145.86M 107.23M
Property plant equipment - 0.87M 0.72M 0.90M 0.22M
Total current assets 3.17M 17.76M 23.04M 36.92M 8.24M
Long term investments - - - - -
Net tangible assets - 2.94M 18.43M 20.35M 4.18M
Short term investments - - - - -
Net receivables - - - 1.13M 0.31M
Long term debt - - - - -
Inventory - - - 0.47M 0.57M
Accounts payable 5.64M 3.36M 2.14M 4.66M 3.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00100M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -117.90400M -101.14700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.28M 0.40M 0.59M 0.61M 0.54M
Deferred long term asset charges - - - - -
Non current assets total 3.23M 3.19M 3.23M 9.12M 8.37M
Capital lease obligations 0.91M 0.94M 0.81M 0.99M 0.22M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.50000M - - - 0.00000M
Change to liabilities 1.21M -8.11300M 4.76M -1.03600M -10.21800M
Total cashflows from investing activities -4.50000M -4.50000M -4.50000M -4.50000M -
Net borrowings - - - - -7.60100M
Total cash from financing activities 24.08M 12.07M 38.44M 19.57M 23.12M
Change to operating activities 4.43M 0.50M 0.83M -1.12400M -2.07000M
Net income -41.30100M -20.69900M -16.75700M -19.29200M -27.67000M
Change in cash -4.23000M -13.94700M 28.02M 1.93M -7.29900M
Begin period cash flow 21.45M 35.40M 7.38M 5.45M 12.75M
End period cash flow 17.23M 21.45M 35.40M 7.38M 5.45M
Total cash from operating activities -23.80900M -26.02100M -10.41700M -17.64300M -30.42200M
Issuance of capital stock 23.99M 9.01M 29.60M 15.97M 31.21M
Depreciation - 5.68M 0.28M 1.70M 3.76M
Other cashflows from investing activities - - - - -
Dividends paid - - - 0.00000M 0.49M
Change to inventory - - - - -
Change to account receivables - - 0.31M - -
Sale purchase of stock - - 38.13M 19.57M 31.21M
Other cashflows from financing activities 0.09M 3.07M 8.84M 3.60M 9.65M
Change to netincome 11.85M 2.29M 0.75M 3.31M 7.55M
Capital expenditures 4.50M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - -10.87800M -19.91800M -27.75100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 28.02M 1.93M -7.29900M
Change in working capital 5.64M -7.61500M 5.59M -1.11200M -10.00600M
Stock based compensation 1.73M 1.01M 0.58M 0.57M 0.40M
Other non cash items 10.12M -4.16400M -0.08700M 0.59M 4.42M
Free cash flow -28.30900M -26.02100M -10.41700M -17.64300M -30.42200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SLS
Sellas Life Sciences Group Inc		 0.72 8.99% 8.77 - - 26.90 5.90 20.84 -1.9556
NVO
Novo Nordisk A/S		 2.50 5.78% 45.69 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.55 1.23% 457.18 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.77 1.60% 600.17 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Sellas Life Sciences Group Inc

Times Square Tower, New York, NY, United States, 10036

Key Executives

Name Title Year Born
Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, Pres, CEO & Director 1976
Ms. Barbara A. Wood Exec. VP, Gen. Counsel & Sec. 1963
Dr. Dragan Cicic M.D., MBA Sr. VP of Clinical Devel. 1963
Mr. John Thomas Burns CPA Sr. VP of Fin. & Chief Accounting Officer 1985
Mr. Robert M. Francomano Sr. VP & Chief Commercial Officer 1967
Mr. Jörg W. Breitkopf Head of Clinical Operations NA
Dr. Angelos M. Stergiou M.D., ScD h.c. Founder, President, CEO & Director 1976
Mr. John Thomas Burns CPA Senior VP & CFO 1985
Ms. Stacy E. Yeung VP, Associate General Counsel & Head of Compliance NA
Dr. Dragan Cicic M.D., MBA Senior Vice President of Clinical Development 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.